24-Hour Crisis Hotline: (877)SAFEGBC or (877)723-3422 Mental Health & Substance Abuse Issues

6502 Nursery Drive, Suite 100
Victoria, TX 77904
(361)575-0611
(800)421-8825
Fax: (361)578-5500

Medical Disorders
Resources
Basic InformationLookupsLatest News
Are Disinfectants Putting Nurses at Risk of COPD?Fat Collects in Lungs, Raising Asthma RiskDrug Limits Damage of Brain InjuryMore Patients With Heart Disease Die at Home Than in HospitalYour Noisy Knees May Be Trying to Tell You SomethingHealth Tip: 10 Ways to Reduce Injury RiskIs That Statin Doing You Any Good?Surgery Helps Tough-to-Treat Acid RefluxBrain Damage From Concussion Evident a Year LaterFor Kids With Genetic Condition, Statins May Be LifesaversNext-Gen Artificial Pancreas Boosts Blood Sugar ControlAHA News: Lowering Blood Pressure May Prevent New Brain Lesions in Older PeopleBladder Drug Can Cause Eye Damage: StudyGood News, Bad News on Concussions in High School SportsSteroid Shots for Painful Joints May Make Matters WorseHealth Tip: Broken Toe CareSleep Apnea Linked to Diabetic Eye DiseaseChildhood Risk Factors Can Predict Adult ObesityHealth Tip: Gum Disease Risk FactorsPut Safety First When Planning to Pack Food-to-GoA Parent's Guide to Managing Kids' Asthma During the FallWhat Foods Are Most Likely to Cause Acne Breakouts?Vision Problems Strike More Than 2 Billion GloballyLight Smoking Causes More Lung Damage Than Once Suspected: StudyHealth Tip: Choking First AidBy Mid-Century, Heat Waves Could Cover Far Bigger AreasGet Vaccinated Before Flu Takes Hold: CDCClose to 1,300 Cases of Vaping-Linked Illness Now IdentifiedMore Years of Football, Higher Odds for Brain Disease LaterPain Relief: When to Use Cold, When to Use HeatAHA News: High Triglycerides Caused a Diet Change – at Age 10Humans May Possess Ability to Regrow CartilageHealth Tip: Recognizing Bedbug Bites'Smartphone Slouching' More Serious Than It SoundsAHA News: What's Your Sense of Purpose? The Answer May Affect Your HealthDeep Brain Stimulation May Relieve Ringing in the Ears: StudyWhat Are the Risks of Pain Relief Alternatives to Opioids?Many ICU Admissions May Be Preventable, Large Study SuggestsCause of Paralyzing Illness in Kids Remains ElusiveFlu Season Is Coming: Here's How to Protect YourselfSinus Infections: What You Need to KnowFewer Teeth, Higher Risk of Heart Disease?Fungal Invasion May Drive Some Pancreatic CancersHealth Tip: Lowering Your Resting Heart RateYour Washer Might Be Breeding Drug-Resistant GermsCan Your Eating Habits Keep Alzheimer's at Bay?Prescription Opioids Linked to Poor Outcomes in Kidney PatientsCases of Serious Vaping-Linked Lung Injury Now Top 1,000Organic Chicken Less Likely to Harbor a Dangerous 'Superbug'Running the Numbers on High Blood Pressure
Questions and AnswersLinks
Related Topics

Diabetes

Evenity Approved for Osteoporotic Women

HealthDay News
by -- Scott Roberts
Updated: Apr 9th 2019

TUESDAY, April 9, 2019 (HealthDay News) -- Evenity (romosozumab) injection has been approved by the U.S. Food and Drug Administration to treat osteoporosis in postmenopausal women at high risk of breaking a bone, the agency said Tuesday in a news release.

More than 10 million people in the U.S. have osteoporosis, making their thinning bones more likely to fracture, the FDA said. Most are women who have gone through menopause.

"Today's approval provides women with postmenopausal osteoporosis who are at high risk of fracture with a new treatment that will reduce this risk," said Dr. Hylton Joffe, director of the agency's Division of Bone, Reproductive and Urologic Products. "But Evenity may increase the risk of heart attack, stroke and cardiovascular death so it's important to carefully select patients for this therapy, which includes avoiding use in patients who have had a heart attack or stroke within the previous year."

Evenity is a monoclonal antibody that blocks the protein sclerostin and helps boost new bone formation. The drug's effectiveness drops after 12 doses, so no one should be given more than that amount, the FDA warned.

Evenity was evaluated in clinical trials involving more than 11,000 women with postmenopausal osteoporosis. The drug increased users' risk of cardiovascular death, heart attack and stroke, prompting the agency to require a boxed warning on the drug's label. Doctors should discontinue Evenity in any woman who has a heart attack or stroke during treatment, the FDA advised.

The most common side effects of Evenity included joint pain and headache.

The drug is produced by Amgen, based in Thousand Oaks, Calif.

More information

Learn more about this approval.